BCL-2 is highly expressed in CLL cells, and venetoclax blocks antiapoptotic BCL-2 signaling by functioning as a BCL-2 homology domain 3 (BH3) mimetic. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.